Threefold Increase in Breast Conservation (BC) in 4172 Patients Accrued During 15 Years of Trials Conducted by the ABCSG.

Sub-category: Breast Cancer
Category: Breast Cancer
Meeting: 2000 ASCO Annual Meeting
Abstract No: 547
Citation: Proc Am Soc Clin Oncol 19: 2000 (abstr 547)
Author(s): Raimund Jakesz

Abstract:

It is well established that BC does not impair the prognosis of patients with breast cancer as compared to mastectomy and should thus be regarded as treatment of choice in stage I and II disease. For various reasons, however, BC has not yet been fully accepted in general practice. Between 1984 and 1998, 4172 patients with hormone-dependent breast cancer were randomized into 5 different trials conducted by the ABCSG. Two of these studies are still in progress, evaluating a direct comparison between tamoxifen and anastrozole (G1, 2) or addition of chemotherapy to tamoxifen. We selected three different patient groups: premenopausal stage II (Group A); postmenopausal stage I (Group B); and postmenopausal stage II (Group C) and compared the BC rate over 15 years, separated for T1 and T2 lesions. In Group A, and within 3 time periods (1984-90, 1991-93, 1994-98), the BC rate (%) increased from 24 to 51 and 71 overall, from 33 to 61 and 83 for T1, and from 23 to 42 and finally 58 for T2. These differences were highly significant in statistical terms (p<0.0001). The local recurrence rate for BC was 5.3% in the 1984-90 time period and 5.1% in 1991-95. As to Group B, 1946 patients were randomized between 1990 and 1998. For all patients, the BC rate increased from 40 to 78% in total, from 50 to 84% for T1, and from 40 to 67% for T2 (p<0.0001). The local recurrence rate after 5 years was 1.5%. In Group C, the BC rate (%) increase 63, from 35, 56, 64 to 75 for T1, and 15, 31, 42 to 50 for T2 (p<0.0001) within 4 time periods (1984-1996-98). The local recurrence rate in this group was 7% for the 1984-90 time period and 3.4% for the conclusion. BC rates can be achieved of up to 80%, depending on tumor size, even in a multicenter adjuvant trial. We believe this significant increase in the BC rate over 15 years of ABCSG trials, which is not counterbalanced by a higher local recurrence rate, reflects an excellent level of surgical quality control. Especially in multi-institutional adjuvant trials in patients with breast cancer, the BC rate should be given high priority.

Associated Presentation(s):
No items found.

Other Abstracts in this Sub-Category:
1. A Randomized Trial Comparing Two Fractionation Schedules for Breast Irrad Postlumpectomy in Node-Negative Breast Cancer.
Meeting: 2000 ASCO Annual Meeting  Abstract No: 5  First Author: Timothy W
Category: Breast Cancer


*Meeting: 2000 ASCO Annual Meeting*  
*Abstract No: 5C*  
*First Author: George Sledge*

Category: Breast Cancer

3. *Incidence of Contralateral Breast Cancer (CBC), Endometrial Cancer (EC), and Thromboembolic Events (TE) in African American (AA) Women Receiving Tamoxifen for Treatment of Primary Breast Cancer.*

*Meeting: 2000 ASCO Annual Meeting*  
*Abstract No: 269*  
*First Author: Worta McCaskill-Stevens*

Category: Breast Cancer

More...

### Abstracts by Raimund Jakesz:

1. *Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.*

*Meeting: 2011 ASCO Annual Meeting*  
*Abstract No: 514*  
*First Author: G. Pfeiler*

Category: Breast Cancer - HER2/ER - ER+

2. *Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT).*

*Meeting: 2011 ASCO Annual Meeting*  
*Abstract No: 556*  
*First Author: S. Loi*

Category: Breast Cancer - HER2/ER - HER2+


*Meeting: 2011 ASCO Annual Meeting*  
*Abstract No: 520*  
*First Author: M. Gnant*

Category: Breast Cancer - HER2/ER - ER+

More...

### Presentations by Raimund Jakesz:

1. *Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)*

*Meeting: 2005 ASCO Annual Meeting*  
*Presenter: Raimund Jakesz*  
*Session: Breast Cancer I (Poster Discussion Session)*
2. Comparison Of Pre-Vs. Postoperative Chemotherapy In Breast Cancer Patients: Four-year Results Of Austrian Breast & Colorectal Cancer Study Group (abcsg) Trial 7

Meeting: 2001 ASCO Annual Meeting
Presenter: Raimund Jakesz, MD
Session: Breast Cancer (General Poster Session)

More...

► Educational Book Manuscripts by Raimund Jakesz:

No items found.